2012 Emerging Science Program Schedule

March 14, 2012

Share:

Following is the schedule of Emerging Science abstracts to be presented at the 2012 AAN Annual Meeting. Abstracts qualify for Emerging Science presentations by having key aspects of research conducted after the October 24th abstract submission deadline and must be new and of sufficient scientific importance to warrant expedited presentation and publication.

The Science Committee is committed to presenting the best neuroscientific research at the Annual Meeting so we are excited to announce that we are accepting 15 abstracts for presentation this year. We are also excited to announce a new format for these presentations. Abstracts will be featured in data blitz format during the first 45 minutes of the session from 5:45 p.m. to 6:30 p.m., followed by poster presentations from 6:30 p.m. to 7:00 p.m.

Emerging Science Session – Wednesday, April 25, 2012
Ernest N. Morial Convention Center, La Nouvelle BALLROOM A/B Theatre, 5:45 PM – 7:00 PM  

001– “Long–Term Efficacy and Augmentation Assessment of a Dopamine Agonist (Pramipexole) Compared with an Alpha–2–Delta Ligand (Pregabalin) in Restless Legs Syndrome: Results of a Randomized, Double–Blinded, Placebo–Controlled Trial”– Diego Garcia–Borreguero, Madrid, Spain

002 – “An International Study Investigating Rotigotine Dose Response (2–8 mg/24 h) on ‘Off’ Time in Advanced Parkinson's Disease”— Lawrence Elmer, Toledo, OH

003 – “Randomized, double–blind, double–dummy study of continuous infusion of levodopa–carbidopa intestinal gel in patients with advanced Parkinson’s disease: Efficacy and safety”—C. Warren Olanow, New York, NY

004 – “A Phase IIb Placebo–Controlled Study of the Exon–Skipping Drug Eteplirsen in Subjects with Duchenne Muscular Dystrophy”—Jerry Mendell, Columbus, OH
005 – “Weekly Assessments of Pain and Sleep During a 17–week, Double–blind, Placebo–controlled Trial of Pregabalin for the Treatment of Chronic Neuropathic Pain After Spinal Cord Injury”—Bruce Parsons, New York, NY

006 – “Brain autopsy and in–vivo cortical brain biopsy trials show a strong concordance between [18F]flutemetamol PET and amyloid–β pathology”—David Wolk, Philadelphia, PA

007 –“[18F]Flutemetamol uptake and cognitive performance in non–demented community–dwelling elders”—Dustin Hammers,  Salt Lake City, UT

008 –“Results of a multicentre phase 3 trial on florbetaben for ß–amyloid brain PET in Alzheimer disease”—Marwan Sabbagh, Scottsdale, AZ

009 –“LCO Spectroscopy of Human Brain Reveals APOE–Isotype–Specific Changes in Protein Aggregate Conformation: Possible Basis for Impaired Aggregate Clearance in the Presence of APOE ε4”—Samuel E. Gandy, New York, NY

010 –“A European consortium for high–profile translational research on early–onset dementia – a prevalence study of the FTLD–ALS causing C9orf72 repeat expansion mutation in an extended European cohort”— Julie van der Zee, Antwerp, Belgium

011 –“The threshold effect of repeated head trauma on brain structure and cognition: The Professional Fighters Brain Health Study” – Charles Bernick, Las Vegas, NV

012–“A novel method for generation of regulatory T cells in auto– reactive T cell culture by Bowman–Birk protease inhibitor”—Mohamad Rostami, Philadelphia, PA

013—“A double–blind, placebo–controlled, Phase 2, 26–week DreaMS trial of a selective S1P receptor agonist ONO?4641 in patients with Relapsing–Remitting Multiple Sclerosis”—Timothy Vollmer, Aurora, CO

014—“Efficacy of two dosing frequencies of subcutaneous interferon beta–1a on the risk of conversion from a first demyelinating event to multiple sclerosis and on MRI measures of disease: 3–year results of Phase III, double–blind, multicentre trials (REFLEX and REFLEXION)”— Mark Freedman, Ottawa, Canada

015—“Efficacy and safety of fingolimod in patients with relapsing–remitting multiple sclerosis (RRMS): Results from an additional 24–month double–blind, placebo–controlled study (FREEDOMS II Study)”— Peter Calabresi, Baltimore, MD